Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 126, Issue 9, 1997, Pages 689-696

  Schuman, Paula ^a   Capps, Linnea ^b   Peng, Grace ^c   Vazquez, Jose ^a   El Sadr, Wafaa ^b   Goldman, Anne I ^d   Alston, Beverly ^c   Besch, C Lynn ^e   Vaughn, Anita ^c   Thompson, Melanie A ^f   Cobb, Malik N ^c   Kerkering, Thomas ^g   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARLEM HOSPITAL CENTER   (United States)

^c University of Minneapolis ^*  (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e TULANE UNIVERSITY MEDICAL CENTER   (United States)

^f AIDS Research Consortium of Atlanta   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

EID: 8244249472     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-9-199705010-00003     Document Type: Article

References (31)

1. Update: AIDS among women - United States, 1994. MMWR Morb Mortal Wkly Rep. 1995;44:81-4
2. Update: Mortality attributable to HIV infection among persons aged 25-44 years - United States, 1994. MMWR Morb Mortal Wkly Rep. 1996;45:121-5.
3. Shiboski CH, Hilton JF, Greenspan D, Westenhouse JL, Derish P, Vranizan K, et al. HIV-related oral manifestations in two cohorts of women in San Francisco. J Acquir Immune Defic Syndr. 1994;7:964-71.
4. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991;5:519-25.
5. Chan IS, Neaton JD, Saravolatz LD, Crane LR, Osterberger J. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. AIDS. 1995;9:1145-51.
6. Rhoads JL, Wright DC, Redfield RR, Burke DS. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA. 1987;257: 3105-7.
7. Iman N, Carpenter CC, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med. 1990;89:142-6.
8. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 1995;50:658-90.
9. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332:700-5.
10. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis. 1995:21(Suppl 1):S99-102.
11. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-25.
12. Deyton L, Carlyn M, Hedderman M, Maiatico G, Hoth D, Fauci A. A national community-based AIDS research program: the community programs for clinical research on AIDS (CPCRA) [Abstract]. Int Conf AIDS. 1991;7:294.
13. Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients with 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother. 1990;34:909-10.
14. Espinel-Ingroff A, Rodriguez-Tudela JL, Martinez-Suarez JV. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol. 1995;33:3154-8.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
16. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: J Wiley; 1986.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-70.
19. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society 1972;34:187-220.
20. Wolfinger R, O'Connell M. Generalized linear models: a pseudo-likelihood approach. Journal of Statistical Computer Simulations. 1993;48:233-43.
21. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991;151:2458-64.
22. Just-Nubling G, Gentschew G, Meissner K, Odewald J, Staszewski S, Helm EB, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis. 1991;10:917-21.
23. Parente F, Ardizzone S, Cernuschi M, Antinori S, Esposito R, Moroni M, et al. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. Am J Gastroenterol. 1994:89:416-20.
24. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect. 1990; 21:55-60.
25. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J Antimicrob Chemother. 1995;35:103-14.
26. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS. 1994;8: 945-50.
27. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidiasis in an HIV cohort. AIDS. 1994;8:787-92.
28. Horn CA, Washburn RG, Givner LB, Peacock JE Jr, Pegram PS. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS [Letter]. AIDS. 1995;9:533-4.
29. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993;17:1018-21.
30. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994;97:339-46.
31. Fitchenbaum CJ, Kletar S, Yiannoutsos C, Chen D, Cohn S, Pottage J, et al. Fluconazole resistant mucosal candidiasis in advanced HIV infection [Abstract]. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996. Vancouver, BC: The International Conference on AIDS; 1996: Mo.B.112.